David C. Myles - Feb 1, 2024 Form 4 Insider Report for Olema Pharmaceuticals, Inc. (OLMA)

Role
CH. DISCOV. & NON-CLIN DEV OFF
Signature
/s/ Shane Kovacs, Attorney-in-Fact
Stock symbol
OLMA
Transactions as of
Feb 1, 2024
Transactions value $
$0
Form type
4
Date filed
2/5/2024, 05:30 PM
Previous filing
Nov 22, 2023

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction OLMA Stock Option (Right to Buy) Award $0 +195K $0.00 195K Feb 1, 2024 Common Stock 195K $15.25 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 25% of the shares subject to the option vest on February 1, 2025 and 1/48 of the total number of shares subject to the option vest each month thereafter, subject to the Reporting Person's continuous service through each applicable vesting date.